FLT3 and acute myeloid leukemia: Furthermore, based on its demonstrated better response and survival outcomes when compared with salvage chemotherapy (SC), the FLT3 inhibitor Gilteritinib was recommended for relapsed or refractory FLT3‐mutated AML in the Perl et al. trial.